$CDRE

Cadre Holdings (CDRE) Q2 2026 Earnings Call Transcript

Cadre Holdings (NYSE:CDRE) reported Q2 2026 net sales of $207.1 million, up 32% year over year, and adjusted EBITDA of $42.0 million, up 56%. The company said backlog reached $368 million and raised full-year revenue guidance to $749 million to $769 million and adjusted EBITDA to $139 million to $144 million. It cited an FBI IDIQ contract and Alien Gear acquisition integration.

Original reporting
Published Aug 12, 2026, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 3:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cadre Holdings (CDRE) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CDREBullishMed
01

Why it matters

The most tradable elements are the raised full-year revenue and adjusted EBITDA guidance, record backlog, and a newly described FBI IDIQ contract using Safariland SXHP ballistic panels. Margin drivers include improved gross margin and mix, offset by FX headwinds and downblending-related pressure in a small nuclear subsegment.

02

Market read

Guidance and backlog updates provide a fresh earnings trajectory, while contract wins and nuclear segment expansion improve visibility into future demand.

03

What to watch

Alien Gear integration and facility closure timing (12 to 18 months) could create cost or disruption not fully captured in near-term margin assumptions; FX headwinds of $6.6M also suggest earnings sensitivity.

Relevance 8/10Novelty 8/10Timing: post-market or late-day Aug 12, 2026 after Q2 call disclosures

Background

Cadre Holdings held its Q2 2026 earnings call, emphasizing acquisition integration, record order backlog, and growth in nuclear safety and monitoring programs.

Company-level read

Ticker impact

$CDREBullishMedium confidence
Context

Cadre reported Q2 net sales of $207.1M, raised full-year revenue guidance to $749M-$769M, and guided adjusted EBITDA to $139M-$144M.

Expected impact

Bias toward upward price reaction versus prior expectations, with volatility around margin and FX sensitivity.

Evidence & confidence

The article discloses multiple fresh, decision-relevant datapoints: raised full-year guidance, Q2 results, backlog records, and a specific government contract. Offsetting risks include FX headwinds and margin pressure in a small nuclear subsegment.

Market effects

Reinforces demand visibility in defense and nuclear-adjacent safety/monitoring equipment, potentially improving read-through for government-contracting peers.

Limited direct regional impact; operations and integration actions are US-focused (Idaho facility closure/integration).

Nuclear and defense procurement themes are globally relevant, but the disclosed catalysts are company-specific and US government oriented.

Counterpoint

Raised guidance may already embed acquisition integration benefits, so investors could focus on execution risk (synergies, margin durability) rather than headline growth.

Key entities

  • Cadre Holdings, Inc.

    NYSE-listed defense and safety products company reporting Q2 results and raised full-year guidance.

  • Alien Gear

    Acquired out of bankruptcy; management projects about $11M full-year 2026 revenue and plans to close the Idaho manufacturing facility over 12 to 18 months.

  • Safariland SXHP ballistic panels

    Ballistic panel technology referenced as integrated into overt armor kits for an FBI IDIQ contract.

  • U.S. military blast monitoring program (BEMO)

    Management cites $18.4M total to date after a second purchase order valued at $8.4M.

Related articles

$RTXHighAI 9/10

Aerospace and Defense Stocks Q2 Highlights: Cadre (NYSE:CDRE)

Cadre (CDRE) is down 8.4% since its Q2 results. RTX (RTX) reported $24.71B revenue, up 14.5% YoY, beating estimates, and raised its full-year EPS guidance. Its stock is up 13.6%. Ducommun (DCO) reported $224.5M revenue, up 11.8% YoY, also beating estimates. Its stock is up 4.3%. The market has shifted focus from AI to geopolitics and back to fundamentals.

$CDREHighAI 9/10

Cadre Holdings, Inc. (CDRE): Results of Operations and Financial Condition

Cadre Holdings, Inc. (CDRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cadre Holdings Reports Second Quarter 2026 Financial Results ​ Grew Quarterly Net Sales 32% and Gross Profit 36% Year-Over-Year ​ Increased Quarterly Adjusted EBITDA and Expanded Adjusted EBITDA Margin Both Sequentially and Year-Over-Year ​ Orders Backlog Increases t

$CDREMedAI 8/10

Cadre Holdings’ (CDRE) Safariland Selected for FBI Ballistic Panel Contract

Cadre Holdings (NYSE:CDRE) said its subsidiary Safariland was selected to supply ballistic panels for an FBI armor contract. Safariland’s SX HP panels will be integrated into Predictive Ballistics’ Overt Armor Kit, after Predictive Ballistics won a five-year, $61 million IDIQ contract for the FBI and other DOJ agencies. The selection followed evaluation versus 11 competitors.

$VGMed

12 Best IPO Stocks with Huge Upside Potential

BNN Bloomberg interview (July 6) with Domini Impact Investments’ Maria Llerena said tech was weak into June but H1 was solid, with semiconductors and chips up nearly 90% by end-June. She cited AI-related CapEx concerns, estimating $800B in 2026, and noted a 50% chance of a Fed hike by year-end. The article then lists IPO stocks, including Venture Global (VG) and Cadre (CDRE).

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.